Hangzhou Alltest Biotech , Ltd. Receivables

Hangzhou Alltest Biotech , Ltd. posts a receivables of $150M as of June 2026. That compares with $160M in the prior-year period — down 3.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Hangzhou Alltest Biotech , Ltd.'s receivables was $160M. The latest reading is $150M — a 3.1% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Hangzhou Alltest Biotech , Ltd.'s financial statement story. At $150M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 688606.SS's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Hangzhou Alltest Biotech , Ltd.'s other metric pages and overview cover the third.